Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Reshma Kewalramani

- PMLiVE

Vertex eyes type 1 diabetes cure with biotech acquisition

Will acquire Semma Therapeutics for $950m

- PMLiVE

Lundbeck’s key products shine in Q2 but problems remain

Faces increasing patent losses

- PMLiVE

Vertex faces rejection of its CF medicines in Scotland

Another rejection over cost-effectiveness

- PMLiVE

Boehringer posts solid first half as business revamp beds in

Jardiance helped to boost sales

Biomarin

BioMarin ticks over in Q2 ahead of gene therapy filing

Haemophilia candidate valrox will be a game-changer for company

- PMLiVE

Leiden reassures on key role at Vertex

Reshma Kewalramani to be new CEO, but Leiden will retain portfolio

- PMLiVE

The Cystic Fibrosis Buyers’ Club

Patients versus Pharma: campaigners using direct action to fight for access

- PMLiVE

Dupixent drives Sanofi again, but other new drugs are lagging

Reported loss due to restructuring

Roche Basel Switzerland

New products help lift Roche outlook despite biosimilar onslaught

Two new cancer therapies approved in Q2

- PMLiVE

Vertex files cystic fibrosis triple therapy with FDA

A landmark for company - but pricing controversy awaits

- PMLiVE

Orkambi row: government now considering Crown Use licensing

MPs call for radical solutions as deadlock remains

- PMLiVE

Buyers’ Club wants government support on Orkambi imports

Proposes three point plan to work round impasse

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links